MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
China Pharma Holdings Cost of Revenue 2011-2025 | CPHI
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.51 M | 7.29 M | 8.6 M | 9.29 M | 8.91 M | 9.44 M | 10.4 M | 10.7 M | 12.4 M | 15.8 M | 17.2 M | 23.4 M | 38.7 M | 52.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.2 M | 6.51 M | 16.5 M |
Quarterly Cost of Revenue China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 816 K | 1.11 M | 1.27 M | - | 1.62 M | 1.94 M | 1.66 M | - | 2.04 M | 1.24 M | 1.78 M | - | 2.1 M | 1.84 M | 1.77 M | - | 2.28 M | 2.34 M | 2.09 M | - | 2.35 M | 2.62 M | 1.57 M | - | 2 M | 2.41 M | 2.27 M | - | 1.79 M | 2.59 M | 2.56 M | - | 2.74 M | 2.27 M | 2.57 M | - | 2.78 M | 3.06 M | 3 M | - | 3.72 M | 4.51 M | 4.43 M | - | 4.06 M | 3.71 M | 4.45 M | - | 5.86 M | 5.85 M | 6.13 M | - | 8.93 M | 10.5 M | 10.8 M | - | 13.5 M | 12.3 M | 11.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 M | 816 K | 3.83 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 0.66 | -0.02 % | $ 46.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.31 | -6.43 % | $ 141 M |  Canada |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 12.63 | 0.72 % | $ 647 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | $ 21.58 | 0.19 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
84 M | $ 6.85 | 0.59 % | $ 425 M | USA |
 |
Harrow Health
HROW
|
39.6 M | $ 50.16 | 2.05 % | $ 1.64 B | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 5.87 | 2.09 % | $ 773 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 26.02 | 1.09 % | $ 1.2 B | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.76 | 1.15 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 4.2 | -1.41 % | $ 59.1 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.6 | 2.45 % | $ 138 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.81 | -0.81 % | $ 18.9 M | USA |
 |
Perrigo Company plc
PRGO
|
2.83 B | $ 13.75 | 0.51 % | $ 1.89 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | $ 0.62 | -10.48 % | $ 9.82 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.77 | -0.56 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 3.64 | 1.68 % | $ 4.52 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.6 | 1.78 % | $ 28.7 M | USA |
 |
Tilray
TLRY
|
480 M | $ 10.15 | -3.61 % | $ 6.27 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 1.7 | 3.66 % | $ 17.7 M | USA |
 |
Veru
VERU
|
11 M | $ 2.34 | 0.86 % | $ 316 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 1.59 | -4.22 % | $ 6.86 M | USA |
 |
Viatris
VTRS
|
9.77 B | $ 12.24 | 1.83 % | $ 14.8 B | USA |
 |
Zomedica Corp.
ZOM
|
7.87 M | - | -0.21 % | $ 98 M | USA |